清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficiency of Electronic Health Record Assessment of Patient-Reported Outcomes After Cancer Immunotherapy

医学 中止 随机对照试验 生活质量(医疗保健) 不利影响 物理疗法 癌症 急诊科 急诊医学 内科学 护理部
作者
Liyan Zhang,Xiaotian Zhang,Lin Shen,Dan Zhu,Saili Ma,Lin Cong
出处
期刊:JAMA network open [American Medical Association]
卷期号:5 (3): e224427-e224427 被引量:65
标识
DOI:10.1001/jamanetworkopen.2022.4427
摘要

Importance: Cancer immunotherapy causes a wide range of immune-related adverse events (irAEs) that require close and timely follow-up. Objectives: To compare the efficiency between electronic patient-reported outcomes (ePRO) and traditional follow-up models in cancer immunotherapy. Design, Setting, and Participants: This open-label randomized clinical trial was performed from September 1, 2019, to March 31, 2021. Patients were randomized to the ePRO model intervention or a control group by a computer system. A total of 28 Chinese tertiary care hospitals participated. Patients who were receiving cancer immunotherapy and could use smartphones or computers were eligible. A total of 300 patients were screened and 278 (92.7%) were enrolled. Interventions: The control group was followed up using traditional methods, including clinic visits every 21 days and telephone follow-up every 3 months. In the intervention group, the ePRO follow-up model included a questionnaire of common symptoms and an image recognition function to evaluate grades of typical irAEs. Patients completed questionnaires weekly and uploaded pictures of results between visits. When grade 1 or 2 irAEs occurred, standardized advice was sent automatically. If grade 3 or 4 irAEs were reported, the model alerted the health care team for assessment and intervention immediately. All patients were followed up for 6 months or until treatment completion. Main Outcomes and Measures: Incidence of serious (grades 3 to 4) irAEs, emergency department (ED) visits, quality of life (QOL), time spent implementing the ePRO model, rate of treatment discontinuation, and death were compared between groups post intervention. Results: A total of 278 patients (mean [SD] age, 58.8 [12.7 (range, 27-78)] years; 206 men [74.1%]) were included in the analysis, consisting of 141 in the intervention group and 137 in the control group. At the postintervention evaluation, the intervention group showed a reduced incidence of serious irAEs (29 of 141 [20.6%] vs 46 of 137 [33.6%]; hazard ratio [HR], 0.51 [95% CI, 0.30-0.88]; P = .01), fewer ED visits (23 of 141 [16.3%] vs 41 of 137 [29.9%]; HR, 0.46 [95% CI, 0.26-0.81]; P = .01), a lower rate of treatment discontinuation (5 of 141 [3.6%] vs 15 of 137 [11.0%]; HR, 0.30 [95% CI, 0.11-0.85]; P = .02), a higher QOL level (mean [SD] score, 74.2 [15.1; 95% CI, 71.7-76.9] vs 64.7 [28.5; 95% CI, 61.0-68.4]; P = .001), and less time implementing follow-up (mean [SD], 8.2 [3.9; 95% CI, 5.0-10.6] minutes vs 36.1 [15.3; 95% CI, 33.6-38.8] minutes; P < .001). However, there were no significant differences between groups in death rates (2 of 141 [1.4%] vs 5 of 137 [3.6%]; HR, 0.38 [95% CI, 0.07-1.99]; P = .28). Conclusions and Relevance: This randomized clinical trial found that the ePRO follow-up model can improve safety and QOL of patients receiving cancer immunotherapy as well as reduce time spent monitoring. This model may provide reliable information and management recommendations. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2100052819.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
顺利的雅旋完成签到,获得积分10
15秒前
善良的金鱼完成签到,获得积分10
24秒前
初景发布了新的文献求助10
42秒前
null的应助被科研通管家采纳,获得10
46秒前
高高仙人掌完成签到,获得积分10
50秒前
殷勤的半凡完成签到,获得积分10
52秒前
安详的老五完成签到,获得积分10
53秒前
火星上的笑寒完成签到,获得积分10
1分钟前
ding的应助被amiee采纳,获得10
1分钟前
含蓄的新柔完成签到,获得积分10
1分钟前
dianeil发布了新的文献求助10
1分钟前
1分钟前
amiee发布了新的文献求助10
1分钟前
somehgo的应助被betsydouglas14采纳,获得30
1分钟前
共享精神的应助被ping采纳,获得10
1分钟前
包容的初阳完成签到,获得积分10
2分钟前
2分钟前
激动的忆翠完成签到,获得积分10
2分钟前
风趣馒头完成签到,获得积分10
2分钟前
2分钟前
无私的碧玉完成签到,获得积分10
2分钟前
俭朴迎荷完成签到,获得积分10
2分钟前
2分钟前
n01W97的应助被科研通管家采纳,获得70
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
怕黑靖荷完成签到,获得积分10
2分钟前
专一的思菱完成签到,获得积分10
2分钟前
2分钟前
欢呼亦绿完成签到,获得积分10
2分钟前
ping发布了新的文献求助10
2分钟前
文静飞松完成签到,获得积分10
3分钟前
喜悦的紫雪完成签到,获得积分10
3分钟前
故意的白风完成签到,获得积分10
3分钟前
要减肥的菀完成签到,获得积分10
4分钟前
矢思然完成签到,获得积分10
4分钟前
蓝意完成签到,获得积分0
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834375
捐赠科研通 7782865
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481280